Post-test

Please mark the single best answer to each question.  The questions with an asterisk are mandatory.  Please answer:

Question Title

* 3. AOA ID Number?
(If you do not have or know your AOA ID, please enter None or Unknown)

Question Title

* 4. Contact Information for Attendee

Question Title

* 5. Primary State or Foreign Country of Practice:

Question Title

* 6. Please select your profession:

Question Title

* 7. I have a Registration with the DEA to prescribe controlled substances (CS)

Question Title

* 8. Do you perform surgical procedures?

Question Title

* 9. Please indicate the primary area of your clinical practice:

Question Title

* 10. How long have you been in clinical practice?

Question Title

* 11. Have you prescribed ER/LA opioids within the past year?

Question Title

* 12. Which comorbid condition may predict the development of chronic pain following acute pain?

Question Title

* 13. Pain secondary to post-herpetic neuralgia is what type of pain?

Question Title

* 14. Which of the following is an anticipated outcome of a patient taking a prescribed opioid medication as recommended?

Question Title

* 15. What is the first step in assessment of a patient’s pain who complains of burning and tingling in his lower extremities?

Question Title

* 16. Which of the following is the most important thing to consider in creating a pain treatment plan?

Question Title

* 17. According to expert guidelines, which of the following is the best sequence for establishing a pain treatment plan of care?

Question Title

* 18. Which side effect of opioid therapy should always prompt proactive treatment?

Question Title

* 19. In which of the following circumstances is the patient at greatest risk of life-threatening respiratory depression from opioid treatment?

Question Title

* 20. Select the correct statement regarding counseling a woman, currently on chronic opioid therapy, who is contemplating a possible pregnancy.

Question Title

* 21. After determining that non-opioid therapies are inadequate for a patient’s pain, which of the following are the three most important things to have in place at the beginning of a trial of opioids?

Question Title

* 22. While all of the following behaviors might merit investigation in a patient receiving long term opioid therapy, which would most strongly prompt your concern for a possible opioid use disorder?

Question Title

* 23. In transitioning an 80 y/o patient from morphine 180 mg/day to oxycodone, and accounting for incomplete cross-tolerance, which one of the following would be an appropriate initial dose? Recall that thirty (30) mg of PO morphine is approximately equianalgesic to 20 mg long-acting oxycodone; that is, the equianalgesic ratio for morphine: oxycodone is 3:2 (although some tables indicate, oxycodone is roughly twice as potent as morphine).

Question Title

* 24. Of the following, which is an appropriate reason for tapering and discontinuing opioid medication and not a situation that calls for further investigation and increased monitoring?

Question Title

* 25. What is the most important piece of information when educating patients and their families about naloxone use?

T